Health

KFSHRC Conducts 48% of Clinical Trials in Saudi Arabia During the First Half of 2025

RIYADH, Saudi Arabia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) led Saudi healthcare…

2 months ago

Allianz Partners appoints Okan zdemir as its new Chief Officer for Health

NEW DELHI and PARIS, Sept. 10, 2025 /PRNewswire/ -- Allianz Partners, a global leader in insurance and assistance services, is…

2 months ago

Havas Health Network Expands into Taiwan, Elevating Health Communications in the Asia-Pacific Region

Havas deepens APAC presence with the launch of Havas Health in Taiwan, an integrated healthcare hub within the Havas Taiwan…

2 months ago

Chiesi Global Rare Diseases Highlights Continued Commitment to Rare Disease Community at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025

September 09, 2025 11:00 ET  | Source: Chiesi Global Rare Diseases Results presented focus on clinical insights on Fabry disease…

2 months ago

KFSHRC Deputy CEO at C3 Davos of Healthcare Summit: AI Will Support, Not Replace, Healthcare Workers

NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Artificial intelligence is ready to play a major role in healthcare, but…

2 months ago

From Confusion to Clarity: How Fincover Is Cracking the Health Insurance Code for Indian Families in 2025

CHENNAI, India, Sept. 9, 2025 /PRNewswire/ -- In India, a single hospital bill can eat up a decade of savings.…

2 months ago

Elevating Healthcare Innovation: ICP DAS-BMP Brings Advanced TPU Portfolio at Medtec China 2025

HSINCHU, Sept. 9, 2025 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane),…

2 months ago

RadNet, Inc. to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9th, 2025

September 08, 2025 12:51 ET  | Source: RadNet, Inc. LOS ANGELES, Sept. 08, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:…

2 months ago

OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders Annual General Meeting of September 30, 2025

OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025 NANTES, France, September…

2 months ago

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder

Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi companyKER-0193, a novel, orally bioavailable…

2 months ago